Medtronic has a new head of investor relations

Medtronic

(NYSE: MDT)
+
announced today that it named Ingrid Goldberg as its new VP and head of investor relations (IR).

Goldberg’s appointment comes as Ryan Weispfenning, who previously held that role, elected to join the company’s Diabetes business and lead the IR function for the unit as it continues to work toward a separation from Medtronic to become MiniMed.

Both changes went into effect today, Dec. 8, 2025. Medtronic said that Weispfenning will support Goldberg and Medtronic for a period of time to ensure a seamless transition.

Weispfenning has more than 25 years of experience at Medtronic, joining its IR team 17 years ago. He led the function at the medtech giant for more than a decade. The company said Weispfenning helped guide it through dynamic business environments while fostering strong relationships with analysts, investors and other global stakeholders.

According to Medtronic, Weispfenning will serve as a key strategic partner to the MiniMed executive team and board of directors. The company expects his experience and leadership to prove important as it works toward the separation of MiniMed.

“After leading Medtronic investor relations for the past decade, I am now honored to help establish the investor relations function for MiniMed as we prepare for its intended separation into an independent, public company,” said Weispfenning. “This is a pivotal moment for the Diabetes business, and I look forward to partnering with the MiniMed leadership team and engaging with the investor community to articulate our long-term strategy, growth opportunities, and commitment to improving outcomes for people living with diabetes worldwide.”

More about the new Medtronic head of IR

Goldberg now joins Medtronic, effective today, with more than 20 years of industry experience. Her track record includes stints in the financial, medical device and life science sectors.

Most recently, Goldberg served as VP of finance and IR at Novocure. There, she led investor relations, communications and business development functions. Before Novocure, she held multiple leadership positions at Abiomed (now part of Johnson & Johnson MedTech).

At Abiomed, Goldberg led IR through a period of significant expansion, Medtronic said. She also previously led IR at Bluebird Bio, a gene and cell therapy developer. Before moving into the healthcare sector, Goldberg spent a decade at Bank of America Merrill Lynch.

“I am thrilled to join Medtronic, an organization whose work transforms patient lives every day,” said Goldberg. “The company’s compelling product portfolio is inspiring, and I am eager to share the progress and innovation that define Medtronic and the people we serve. It is a privilege to contribute to a company so deeply committed to improving human health.”